- China Biologic Products taps Stanley Lau for president
China-based plasma-based biopharmaceutical China Biologic Products Inc. (NSDQ:CBPO), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co. Ltd., and its equity investment in Xi’an Huitian Blood Products Co. Ltd., on Dec. 1 announced that its board named Stanley Lau to the position of president.
- Osseon therapeutics names Gary Coughlen new CFO
Osseon Therapeutics Inc. on Dec. 9 named Gary Coughlen as the company’s chief financial officer, effective immediately. Mr. Coughlen was most recently the CFO of PolyRemedy, Inc., a private-equity medical device company focused on wound care management.
- Dr. N. Anthony Coles named to LabCorp board
Laboratory Corporation of America Holdings (NYSE:LH) today announced that Dr. N. Anthony Coles has been elected to its board, effective Jan. 1, 2011. Dr. Coles is CEO of Onyx Pharmaceuticals Inc. and a member of its board.
- Uroplasty announces addition of Robert Kill to its board
Uroplasty, Inc. (NSDQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors. Mr. Kill’s appointment increases the membership on the board to seven.
- Cook Medical names Phil Nowell vice president, aortic intervention
Phil Nowell, who has served as global leader of Cook Medical’s growing aortic intervention business unit since February 2008, was promoted to VP of that division on Dec. 7.
- Stryker announces election of new director
Stryker Corp. (NYSE:SYK) announced an increase in the size of its Board of Directors to ten and the election of Allan Golston as a director, effective January 1, 2011.
- RainDance Technologies appoints Mark Dronsfield director of sales, Europe
RainDance Technologies Inc., a private company pioneering microdroplet-based technologies for single molecule and single cell analysis, today announced the latest addition to its worldwide commercial leadership team with the appointment of Mark Dronsfield as director of sales for Europe. Dronsfield joins a growing commercial team of industry veterans that includes Richard Lussier, VP of worldwide sales and Ingrid Choupin, managing director of European sales and marketing.
- Cell Biologist Carolina Allers joins TCA Cellular Therapy
TCA Cellular Therapy, an adult stem cell biotherapeutics company is pleased to announce the addition of Carolina Allers as director of cell processing. Allers will work directly with scientific director Jose Minguell in TCA Cellular’s laboratory in research and adult stem cell processing.
- California Healthcare Institute appoints new vice president – state government affairs
California Healthcare Institute today announced the appointment of Consuelo Hernandez as vice president of state government affairs. CHI is a non-profit public policy research organization for California’s biomedical R&D industry.
- Jeremy Berg to step down as National Institute of General Medical Sciences director
Jeremy Berg, director of the National Institutes of Health’s National Institute of General Medical Sciences (NIGMS) since Nov. 2003, announced today that he will step down from his post to become associate senior vice chancellor for science strategy and planning in the health sciences at the University of Pittsburgh.
- Vermillion reappoints three directors, approves a new stock incentive plan
Following the annual meeting of its stockholders on Dec. 3, Vermillion Inc. (NYSE:VRML) announced that its stockholders approved the reappointment of Gail Page, John Hamilton and Dr. William Wallen as directors of the Company. In addition, shareholders approved the 2010 Stock Incentive Plan and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm.
- unithink names John Cline CEO
unithink NV announced that it named John Cline CEO of the company. Cline comes to unithink after successful stints at National Clinical Research and etrials, where he was a founder and CEO.